Table S1. Adverse events reported following the administration of a single oral dose of 200 mg grazoprevir with or without the coadministration of multiple twice-daily oral doses of 100 mg ritonavir for 15 days to healthy adult participants (Trial 1)[a]

Adverse event, n (%)	**GZR alone (*N* = 10)**	**RTV alone (*N* = 10)**	**GZR + RTV (*N* = 10)**
Vision blurred	0 (0)	1 (10.0)	0 (0)
Abdominal discomfort	0 (0)	1 (10.0)	1 (10.0)
Abdominal distension	0 (0)	1 (10.0)	0 (0)
Abdominal pain	0 (0)	0 (0)	1 (10.0)
Diarrhea	0 (0)	1 (10.0)	1 (10.0)
Dyspepsia	0 (0)	1 (10.0)	0 (0)
Flatulence	0 (0)	1 (10.0)	0 (0)
Nausea	1 (10.0)	0 (0)	1 (10.0)
Discomfort	0 (0)	0 (0)	1 (10.0)
Fatigue	0 (0)	3 (30.0)	2 (20.0)
Hangover	0 (0)	0 (0)	1 (10.0)
Impetigo	0 (0)	0 (0)	1 (10.0)
Upper respiratory tract infection	0 (0)	0 (0)	1 (10.0)
Foreign body in eye	1 (10.0)	0 (0)	0 (0)
Laceration	0 (0)	1 (10.0)	0 (0)
Dizziness	0 (0)	0 (0)	1 (10.0)
Headache	3 (30.0)	3 (30.0)	5 (50.0)
Syncope	0 (0)	0	1 (10.0)
Oropharyngeal pain	0 (0)	1 (10.0)	0 (0)

[a]Abbreviations: GZR, grazoprevir; RTV, ritonavir.

Table S2. Adverse events reported following coadministration of grazoprevir 200 mg once daily and 300 mg atazanavir/100 mg ritonavir once daily, 400 mg lopinavir/100 mg ritonavir twice daily, or 600 mg darunavir/100 mg ritonavir twice daily for 7 days vs administration of grazoprevir 200 mg once daily for 7 days to healthy adult participants (Trial 2)[a]

Adverse event, n (%)	**GZR alone (*N* = 13)**	**ATV/RTV alone (*N* = 12)**	**GZR + ATV/RTV (*N* = 11)**
Abnormal sensation in eye	0 (0)	0 (0)	1 (9.1)
Diarrhea	0 (0)	1 (8.3)	0 (0)
Flatulence	0 (0)	1 (8.3)	0 (0)
Nausea	1 (7.7)	2 (16.7)	0 (0)
Vomiting	1 (7.7)	0 (0)	0 (0)
Chest pain	0 (0)	1 (8.3)	0 (0)
Vessel puncture–site pruritus	1 (7.7)	0 (0)	0 (0)
Vessel puncture–site reaction	1 (7.7)	0 (0)	0 (0)
Upper respiratory tract infection	0 (0)	1 (8.3)	0 (0)
Dizziness	0 (0)	1 (8.3)	0 (0)
Headache	0 (0)	3 (25.0)	1 (9.1)
Paresthesia	1 (7.7)	0 (0)	0 (0)
Somnolence	0 (0)	0 (0)	1 (9.1)
Anxiety	1 (7.7)	0 (0)	0 (0)
Insomnia	1 (7.7)	0 (0)	0 (0)
Dyspnea	1 (7.7)	0 (0)	0 (0)
Oropharyngeal pain	0 (0)	1 (8.3)	0 (0)
Productive cough	0 (0)	1 (8.3)	0 (0)
Rhinorrhea	0 (0)	1 (8.3)	0 (0)
Erythema	0 (0)	0 (0)	1 (9.1)
Pruritus, generalized	0 (0)	1 (8.3)	0 (0)
Rash, maculo-papular	0 (0)	1 (8.3)	0 (0)
Vitiligo	0 (0)	0 (0)	1 (9.1)
Adverse event, n (%)	**GZR alone (*N* = 13)**	**LPV/RTV alone (*N* = 13)**	**GZR + LPV/RTV (*N* = 13)**
Abdominal pain	0 (0)	1 (7.7)	0 (0)
Constipation	1 (7.7)	0 (0)	0 (0)
Diarrhea	0 (0)	3 (23.1)	0 (0)
Nausea	0 (0)	1 (7.7)	0 (0)
Upper respiratory tract infection	0 (0)	1 (7.7)	0 (0)
Viral infection	1 (7.7)	2 (15.4)	0 (0)

Alanine aminotransferase increased	0 (0)	0 (0)	1 (7.7)
Gamma-glutamyltransferase increased	0 (0)	0 (0)	1 (7.7)
Neutrophil count decreased	0 (0)	0 (0)	1 (7.7)
Decreased appetite	0 (0)	1 (7.7)	0 (0)
Flank pain	1 (7.7)	0 (0)	0 (0)
Headache	2 (15.4)	3 (23.1)	1 (7.7)
Memory impairment	0 (0)	1 (7.7)	0 (0)
Paresthesia	0 (0)	1 (7.7)	0 (0)
Epistaxis	0 (0)	0 (0)	1 (7.7)
Productive cough	0 (0)	0 (0)	1 (7.7)
Adverse event, n (%)	**GZR alone (*N* = 13)**	**DRV/RTV alone (*N* = 12)**	**GZR + DRV/RTV (*N* = 12)**
Abdominal pain, upper	1 (7.7)	0 (0)	0 (0)
Nausea	1 (7.7)	0 (0)	0 (0)
Vomiting	1 (7.7)	0 (0)	0 (0)
Upper respiratory tract infection	0 (0)	2 (16.7)	1 (8.3)
Alanine aminotransferase increased	1 (7.7)	0 (0)	0 (0)
Flank pain	0 (0)	0 (0)	1 (8.3)
Neck pain	0 (0)	0 (0)	1 (8.3)
Headache	2 (15.4)	2 (16.7)	1 (8.3)
Dysphonia	0 (0)	1 (8.3)	0 (0)
Papule	0 (0)	1 (8.3)	0 (0)

[a]Abbreviations: ATV, atazanavir; DRV, darunavir; GZR, grazoprevir; LPV, lopinavir; RTV, ritonavir.

Table S3. Adverse events reported following coadministration of elbasvir 50 mg once daily and 300 mg atazanavir/100 mg ritonavir once daily, 400 mg lopinavir/100 mg ritonavir twice daily, or 600 mg darunavir/100 mg ritonavir twice daily for 7 days vs administration of grazoprevir 200 mg once daily for 7 days to healthy adult participants (Trial 3)[a]

Adverse event, n (%)	**EBR alone (*N* = 10)**	**ATV/RTV alone (*N* = 10)**	**EBR + ATV/RTV (*N* = 8)**
Jaundice	0 (0)	1 (10.0)	0 (0)
Excoriation	0 (0)	1 (10.0)	0 (0)
Dizziness, postural	1 (10.0)	0 (0)	0 (0)
Dysgeusia	1 (10.0)	0 (0)	0 (0)
Headache	1 (10.0)	1 (10.0)	0 (0)
Nasal congestion	0 (0)	1 (10.0)	0 (0)
Oropharyngeal pain	0 (0)	1 (10.0)	0 (0)
Rhinorrhea	1 (10.0)	1 (10.0)	0 (0)
Sinus congestion	1 (10.0)	0 (0)	0 (0)
Pruritus	0 (0)	1 (10.0)	0 (0)
Rash, maculo-papular	0 (0)	1 (10.0)	0 (0)
Adverse events, n (%)	**EBR Alone (*N* = 10)**	**LPV/RTV (*N* = 10)**	**EBR + LPV/RTV (*N* = 9)**
Abdominal pain	1 (10.0)	2 (20.0)	0 (0)
Diarrhea	0 (0)	6 (60.0)	2 (22.2)
Dyspepsia	1 (10.0)	2 (20.0)	1 (11.1)
Flatulence	1 (10.0)	0 (0)	0 (0)
Nausea	1 (10.0)	1 (10.0)	0 (0)
Vomiting	0 (0)	1 (10.0)	1 (11.1)
Asthenia	0 (0)	1 (10.0)	0 (0)
Irritability	1 (10.0)	0 (0)	0 (0)
Herpes zoster	0 (0)	0 (0)	1 (11.1)
Oral herpes	1 (10.0)	0 (0)	0 (0)
Upper respiratory tract infection	0 (0)	0 (0)	1 (11.1)
Musculoskeletal stiffness	1 (10.0)	0 (0)	0 (0)
Myalgia	1 (10.0)	0 (0)	0 (0)
Headache	1 (10.0)	0 (0)	1 (11.1)
Libido decreased	1 (10.0)	0 (0)	0 (0)
Nervousness	0 (0)	1 (10.0)	0 (0)
Menstrual disorder	0 (0)	1 (10.0)	0 (0)
Metrorrhagia	0 (0)	1 (10.0)	0 (0)
Oropharyngeal pain	1 (10.0)	0 (0)	0 (0)
Rhinorrhea	0 (0)	0 (0)	1 (11.1)

Adverse event, n (%)	**EBR alone (*N* = 10)**	**DRV/RTV alone (*N* = 10)**	**EBR + DRV/RTV (*N* = 8)**
Dyspepsia	1 (10.0)	0 (0)	0 (0)
Flatulence	0 (0)	1 (10.0)	1 (12.5)
Nausea	1 (10.0)	0 (0)	0 (0)
Irritability	0 (0)	1 (10.0)	0 (0)
Headache	1 (10.0)	1 (10.0)	0 (0)
Abnormal dreams	0 (0)	1 (10.0)	0 (0)
Dysmenorrhea	0 (0)	1 (10.0)	0 (0)
Cough	0 (0)	1 (10.0)	0 (0)
Rhinorrhea	0 (0)	1 (10.0)	0 (0)
Pruritus	0 (0)	1 (10.0)	0 (0)
Rash maculo-papular	0 (0)	1 (10.0)	0 (0)
Rash papular	0 (0)	1 (10.0)	0 (0)

[a]Abbreviations: ATV, atazanavir; DRV, darunavir; EBR, elbasvir; LPV, lopinavir; RTV, ritonavir.